Accolade, Inc. (ACCD) Research

Accolade, Inc., along with its subsidiaries, specializes in providing innovative, technology-driven solutions across the United States. These solutions are designed to empower individuals to better understand, navigate, and ultimately leverage both the complex healthcare system and their available workplace benefits. At the core of its offering is a robust cloud-based platform that delivers comprehensive, multimodal support. This assistance comes from a dedicated team of health assistants and clinical professionals, including registered nurses, physician medical directors, and specialists in behavioral health. Furthermore, Accolade extends its services to include valuable second opinion consultations and crucial decision-making support for healthcare matters. The company primarily serves employers who aim to furnish their employees and their families with a unified, easily accessible resource for all their health, medical care, and benefits-related inquiries. Established in 2007, Accolade, Inc. maintains its corporate headquarters in Plymouth Meeting, Pennsylvania.

Market snapshot

Symbol
ACCD
Price
$7.02
Day change
0.00%
Market cap
$575.6M
P/E ratio
-5.27x
52-week range
3.08-9.67
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Analyst price target
$13.97

Peer companies

  • Apollo Endosurgery, Inc. (APEN)
  • BioDelivery Sciences International, Inc. (BDSI)
  • Claritev Corporation (CTEV)
  • Exscientia plc (EXAI)
  • MultiPlan Corporation (MPLN)
  • Regulus Therapeutics Inc. (RGLS)
  • Sage Therapeutics, Inc. (SAGE)
  • Sharecare, Inc. (SHCR)

Recent insider activity

  • SINGH RAJEEV — A-Award (175000 shares) on 2025-04-08
  • SINGH RAJEEV — A-Award (136293 shares) on 2025-04-08
  • SINGH RAJEEV — D-Return (175000 shares) on 2025-04-08
  • SINGH RAJEEV — D-Return (904809 shares) on 2025-04-08
  • SINGH RAJEEV — D-Return (18125 shares) on 2025-04-08

Open Accolade, Inc. (ACCD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.